Related Experiment Video
Updated: Jul 5, 2025
Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
Published on: August 17, 2022
Immune cells and related cytokines in dilated cardiomyopathy
Jingdi Zhang1, Linlin Cheng1, Zhan Li1
1Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Insights
Dilated cardiomyopathy (DCM) involves immune cells and inflammation in its development. Understanding this immunopathogenesis may reveal new biomarkers and treatments for heart failure.
Area of Science:
- Cardiology
- Immunology
- Pathogenesis
Background:
- Dilated cardiomyopathy (DCM) is a myocardial disease characterized by structural and functional cardiac dysfunction.
- DCM increases the risk of heart failure (HF) and involves complex underlying etiologies.
- Immune cell activation and inflammatory cascades are increasingly recognized as key players in DCM pathogenesis.
Purpose of the Study:
- To review the role of immune cells and cytokines in the pathogenesis of DCM.
- To explore potential immunotherapy strategies for treating DCM.
Main Methods:
- Literature review of studies on DCM immunopathogenesis.
- Analysis of the involvement of specific immune cells and cytokines.
- Examination of current and emerging immunotherapy approaches.
Main Results:
- Immune cells and inflammatory mediators significantly contribute to myocardial damage and remodeling in DCM.
- Aberrant immune system activation drives sustained inflammation in DCM.
- Specific cytokines are implicated in the progression of DCM.
Conclusions:
- Immune responses are central to DCM development and progression.
- Targeting immune pathways offers potential therapeutic avenues for DCM.
- Further research into DCM immunopathogenesis can identify novel biomarkers and treatments.
Abstract:
Dilated cardiomyopathy (DCM) is a non-ischemic cardiomyopathy involving one or more underlying etiologies. It is characterized by structural and functional dysfunction of the myocardium, potentially leading to fibrosis and ventricular remodeling, and an elevated risk of heart failure (HF). Although the pathogenesis of DCM remains unknown, compelling evidence suggests that DCM-triggered immune cells and inflammatory cascades play a crucial role in the occurrence and development of DCM. Various factors are linked to myocardial damage, inducing aberrant activation of the immune system and sustained inflammatory responses in DCM. The investigation of the immunopathogenesis of DCM also contributes to discovering new biomarkers and therapeutic targets. This review examines the roles of immune cells and related cytokines in DCM pathogenesis and explores immunotherapy strategies in DCM.
Related Concept Videos
01:26Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
01:17Pathophysiology of Heart Failure